Cilo Cybin Holdings Limited, incorporated in South Africa, is set to list on the JSE’s AltX market. The company, registered on February 23, 2022, will begin trading on June 25, 2024. Cilo Cybin will list all 71,017,906 ordinary shares as a Special Purpose Acquisition Company (SPAC). The JSE share code is “CCC” with ISIN: ZAE000310397.
Company Background
Cilo Cybin was founded by Gabriel Theron. The company aims to invest in the biotech, biohacking, and pharmaceutical sectors. They focus on using Artificial Intelligence (AI) and medical expertise to deliver personalized health solutions. Their goal is to improve customer health, performance, and longevity.
Listing Requirements
Cilo Cybin meets the JSE AltX minimum issued capital requirement of R50 million. The company also meets the 10% public shareholder spread requirement. These criteria are essential for their listing as a SPAC.
Investment Strategy
Cilo Cybin plans to acquire and invest in businesses within the biotech, biohacking, and pharmaceutical industries. The company seeks assets that can enhance their service and product offerings. They aim to improve profitability and maximize shareholder returns.
Key Investment Criteria
- Assets in the pharmaceutical, biotech, or biohacking sectors
- Globally positioned assets
- Potential for cash generation or value increase
ALPS and Dr. Tham Investment
ALPS and Dr. Tham each subscribed for 28,762,252 ordinary shares in Cilo Cybin. This investment represents a 40.5% shareholding for each, totaling USD 3 million. ALPS, based in Kuala Lumpur, Malaysia, is a biotech research, medical, and wellness company. They focus on predictive, precision, and preventive health management.
Synergies with ALPS
ALPS and Cilo Cybin share a mutual focus on personalized and preventative medicine. Both companies work in the medicinal cannabis and psychedelic products sectors. ALPS’ merger with Globalink Investment Inc., valued at USD 1.6 billion, will form Alps Life Science Inc., expected to list on Nasdaq.
Company Management
Cilo Cybin’s board of directors includes a mix of South African and Malaysian nationals. The CEO is Gabriel Theron, and the CFO is HB Aucamp. Dr. Seng Kong Tham serves as the non-executive chairman.
Board of Directors
| Name | Age | Nationality | Designation |
|---|---|---|---|
| Gabriel Theron | 43 | South African | Chief Executive Officer, Founder |
| HB Aucamp | 74 | South African | Chief Financial Officer |
| Dr. Seng Kong Tham | 55 | Malaysian | Non-executive Chairman |
| Sakekile Baduza | 45 | South African | Lead Independent Non-Executive Director |
| Jessica Moodley Theron | 42 | South African | Non-executive Director |
| Yoke Ling Chew | 53 | Malaysian | Non-executive Director |
| Mohd Razef Bin Abdullah | 74 | Malaysian | Independent Non-Executive Director |
| Lisa Teoh | 54 | Malaysian | Non-executive Director |
| Wei Sim Low | 29 | Malaysian | Independent Non-Executive Director |
Dates and Times for Listing
The proposed listing date for Cilo Cybin is June 25, 2024, at 09h00. This marks a significant milestone for the company as it enters the public market.
Access to Pre-Listing Statement
The Pre-Listing Statement is available in English on the company’s website. Copies can also be obtained at the company’s registered office and the Designated Advisor’s office during business hours.
Conclusion
Cilo Cybin’s listing on the JSE AltX market as a SPAC is a strategic move. It aims to leverage its expertise in biotech and pharmaceuticals. The company’s collaboration with ALPS highlights its commitment to personalized health solutions. Investors are encouraged to review the Pre-Listing Statement for detailed information.